Corona Remedies Ltd

Corona Remedies Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Corona Remedies Ltd

₹ 1,789 4.86%
14 May 2:15 p.m.
coronaremedies.com BSE: 544644 NSE: CORONA
About

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]

[ add key points ]
Website BSE NSE
  • Market Cap ₹ 10,942 Cr.
  • Current Price ₹ 1,789
  • High / Low ₹ 1,951 / 1,337
  • Stock P/E 54.8
  • Book Value ₹ 122
  • Dividend Yield 0.57 %
  • ROCE 33.2 %
  • ROE 29.5 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%

Cons

  • Stock is trading at 14.8 times its book value
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE IPO Nifty Microcap 250 Nifty Total Market Nifty IPO

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
314 298 294 347 361 342 353
247 228 239 277 283 259 291
Operating Profit 67 69 54 70 78 83 62
OPM % 21% 23% 18% 20% 22% 24% 18%
2 1 2 2 2 -17 4
Interest 3 2 2 2 2 2 1
Depreciation 9 10 10 9 9 9 10
Profit before tax 57 58 44 61 70 55 55
Tax % 25% 23% 28% 24% 25% 25% 17%
43 45 32 46 52 41 45
EPS in Rs 7.03 7.35 5.16 7.55 8.55 6.75 7.41
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
884 1,014 1,196 1,403
756 859 956 1,110
Operating Profit 128 156 241 293
OPM % 14% 15% 20% 21%
7 5 6 -8
Interest 4 14 11 7
Depreciation 20 28 37 38
Profit before tax 111 118 199 240
Tax % 23% 24% 25% 23%
85 90 149 185
EPS in Rs 13.89 14.80 24.43 30.27
Dividend Payout % 20% 25% 30% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 17%
TTM: 17%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 33%
TTM: 33%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 27%
Last Year: 30%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 61 61 61 61
Reserves 347 419 545 686
28 159 86 165
159 191 237 293
Total Liabilities 595 831 930 1,205
185 384 370 580
CWIP 65 121 186 143
Investments 32 26 26 0
314 301 348 482
Total Assets 595 831 930 1,205

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
103 157 190 229
-50 -267 -84 -256
-45 99 -107 25
Net Cash Flow 8 -11 0 -1
Free Cash Flow 9 -129 99 56
CFO/OP 100% 112% 97% 95%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 36 36 36 38
Inventory Days 182 158 200 175
Days Payable 163 184 221 206
Cash Conversion Cycle 55 10 14 7
Working Capital Days 30 -2 9 -15
ROCE % 25% 32% 33%

Insights

In beta
Mar 2023 Mar 2024 Jun 2025
Actual Production - Total (Tablets/Capsules)
Million Units

Log in to view insights

Please log in to see hidden values.

Login
Capacity Utilization - Bhayla Tablets/Capsules
Percentage ・Standalone data
Chronic Segment Contribution to Revenue
Percentage
Installed Capacity - Tablets/Capsules (Total)
Million Units
IPM Market Rank
Rank
Market Share in Total IPM
Percentage
Number of Medical Representatives
Number
Number of Brands with Sales > INR 10 Crores
Number
Number of Distributors
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2025Mar 2026
69.00% 69.00%
1.84% 2.25%
6.77% 7.02%
22.41% 21.75%
No. of Shareholders 31,03519,609

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings

Concalls